臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 2826576
	???header.visitor??? : 32006123 ???header.onlineuser??? : 1060 ???header.sponsordeclaration???

???search.scope???

???search.advance???

???search.login???

???search.administrator???

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

???ui.leftmenu.abouttair???
	???ui.leftmenu.explanation???

???ui.leftmenu.bartitle???
	Repositories
	Author
	Title
	Date
	???ui.leftmenu.statisticschart???
	???ui.leftmenu.realtimefacts???
	???ui.leftmenu.trend???

???index.news???
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

???ui.leftmenu.copyrighttitle???
	???ui.leftmenu.copyrightpublisher???
	???ui.leftmenu.copyrightconference???

???ui.leftmenu.link???
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"schellens j h m"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1???	???jsp.browse.items-by-author.order2???

Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2022-09-15T01:08:59Z	A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors	Naing A.; Gainor J.F.; Gelderblom H.; Forde P.M.; Butler M.O.; Chia-Chi Lin; Sharma S.; Ochoa De Olza M.; Varga A.; Taylor M.; Schellens J.H.M.; Wu H.; Sun H.; Silva A.P.; Faris J.; Mataraza J.; Cameron S.; Bauer T.M.
臺大學術典藏	2022-08-19T00:20:33Z	Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYnote-028 study	?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; CHIUN HSU; Le Tourneau C.; Hollebecque A.
臺大學術典藏	2021-02-18T01:45:22Z	Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study	Mehnert J.M.;Bergsland E.;O??Neil B.H.;Santoro A.;Schellens J.H.M.;Cohen R.B.;Doi T.;Ott P.A.;Pishvaian M.J.;Puzanov I.;Aung K.L.;Chiun Hsu;Le Tourneau C.;Hollebecque A.;?Lez E.;Tamura K.;Gould M.;Yang P.;Stein K.;Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; Chiun Hsu; Le Tourneau C.; Hollebecque A.; ?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A.
臺大學術典藏	2020-05-25T07:35:01Z	A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors	Naing A; Gainor J.F; Gelderblom H; Forde P.M; Butler M.O; Chia-Chi Lin; Sharma S; Ochoa De Olza M; Varga A; Taylor M; Schellens J.H.M; Wu H; Sun H; Silva A.P; Faris J; Mataraza J; Cameron S; Bauer T.M.

Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page